As increasing pre-clinical evidence from mouse models and also from genome-wide analyses revealed an important role of p53 in the pathogenesis of pancreatic cancer the investigators decided to also include this marker in the current translational analysis from AIO-PK0104[18, 19]. This evidence concerns the gene TP53 and familial pancreatic carcinoma.